Logo

PMVP

PMV Pharmaceuticals, Inc.

PMVP

PMV Pharmaceuticals, Inc. • NASDAQ
$1.32 ▼ -1.49% (-0.02)
Market Cap $70.24 M
52w High $1.84
52w Low $0.81
Dividend Yield 0%
P/E -0.83
Volume 140.71K
Outstanding Shares 53.21M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $22.49M ▼ $-21.059M ▲ 0% $-0.397 ▲ $-21.033M ▲
Q2-2025 $0 $22.847M ▲ $-21.21M ▼ 0% $-0.41 ▼ $-21.173M ▲
Q1-2025 $0 $21.564M ▼ $-17.436M ▲ 0% $-0.34 ▼ $-21.527M ▲
Q4-2024 $0 $25.168M ▲ $-23M ▼ 0% $0.37 ▲ $-25.129M ▼
Q3-2024 $0 $21.888M $-19.226M 0% $-0.37 $-21.517M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $129.25M ▼ $133.844M ▼ $12.845M ▲ $120.999M ▼
Q2-2025 $142.274M ▼ $152.855M ▼ $12.25M ▲ $140.605M ▼
Q1-2025 $160.388M ▼ $170.608M ▼ $10.501M ▼ $160.107M ▼
Q4-2024 $169.454M ▼ $191.288M ▼ $15.208M ▼ $176.08M ▼
Q3-2024 $182.841M $223.495M $25.587M $197.908M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-21.059M ▲ $-19.82M ▼ $12.028M ▲ $0 ▼ $-7.79M ▼ $-19.819M ▼
Q2-2025 $-21.21M ▼ $-18.302M ▼ $10.986M ▼ $103K ▲ $-7.214M ▼ $-18.313M ▼
Q1-2025 $-17.436M ▲ $-18.266M ▼ $28.714M ▲ $10K ▼ $10.465M ▲ $-18.27M ▼
Q4-2024 $-23M ▼ $-16.661M ▲ $7.744M ▼ $172K ▲ $-8.756M ▼ $-16.717M ▲
Q3-2024 $-19.226M $-16.839M $17.119M $0 $284K $-16.84M

Five-Year Company Overview

Income Statement

Income Statement PMV is still a pure research and development company with no product revenue yet. The income statement is dominated by R&D and related operating costs, which lead to consistent yearly losses. Those losses have been relatively steady rather than sharply accelerating, and per‑share losses have actually improved over time as spending has stabilized. Overall, the profile is typical for a clinical‑stage biotech: costs to push the lead drug through trials, offset by no commercial income yet, so profitability is not in sight until and unless a drug is approved and launched.

Balance Sheet

Balance Sheet The balance sheet shows a company funded mainly by equity with very little use of debt. Total assets and shareholders’ equity have gradually drifted down as cash is used to fund operations, which is expected at this stage. Cash levels are much lower than right after the IPO but have been relatively stable more recently, suggesting some discipline in spending. The almost debt‑free structure reduces financial leverage risk, but the shrinking asset and equity base underline the dependence on future trial success or new funding to rebuild financial strength over time.

Cash Flow

Cash Flow Cash flows mirror the income statement: the company consistently uses cash in its operations to pay for R&D, trials, and overhead, with no offsetting inflows from product sales. Capital spending is minimal, so almost all cash usage is tied directly to running and advancing the pipeline rather than to heavy equipment or facilities. The burn rate appears measured rather than extreme, but it is persistent. Management’s own guidance suggests that current cash should cover operations into the period when key clinical and regulatory milestones are expected, which makes timing and execution of those milestones critical. Beyond that point, the company would likely need either partnership income, new capital, or commercial revenue to sustain itself.

Competitive Edge

Competitive Edge PMV is trying to define a new niche in oncology by reactivating mutant p53, a very important cancer‑related protein. Its lead drug, rezatapopt, targets a specific p53 mutation and has first‑mover status in this very focused space. The company’s roots in foundational p53 science, combined with a growing patent portfolio and a highly targeted, mutation‑specific approach, form the core of its competitive edge. At the same time, this is a high‑risk, early field with emerging competitors and no approved p53‑reactivating drugs yet. The company is somewhat concentrated around a single lead asset, so its competitive position is powerful if that drug works and gains approval, but vulnerable if clinical or regulatory outcomes disappoint.

Innovation and R&D

Innovation and R&D Innovation is PMV’s main asset. The company is built around deep expertise in p53 biology and a precision oncology platform designed to “fix” specific mutant forms of p53 rather than broadly killing dividing cells. Rezatapopt, its lead pill‑based drug, is designed to restore normal function to one particular p53 mutation and has shown encouraging signals across several tumor types, including ovarian cancer. PMV is also working on companion diagnostics and exploring combinations with other cancer drugs, which, if successful, could broaden the impact of its approach. Behind the lead program, there are early efforts aimed at other p53 mutations, suggesting a potential long‑term pipeline, though details remain limited and early‑stage.

Summary

PMV is a classic clinical‑stage biotech: no revenue, meaningful but controlled losses, and a balance sheet that is still equity‑rich but gradually eroding as cash funds R&D. The company’s fate is closely tied to the success of its first‑in‑class p53‑reactivating drug, rezatapopt, and to its ability to hit clinical and regulatory milestones on roughly the same timeline as its cash runway. Scientifically, PMV operates on a strong and differentiated foundation with deep p53 know‑how, a focused precision platform, and solid intellectual property. Commercially and financially, however, it remains highly uncertain: there is no approved product, the business is concentrated around one main asset, and future funding needs will depend heavily on trial results, regulatory feedback, and potential partnerships. The company offers a blend of high scientific ambition and correspondingly high execution and development risk.

NEWS

October 24, 2025 · 11:39 AM UTC

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Read more

September 10, 2025 · 7:00 AM UTC

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Read more